BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1057 related articles for article (PubMed ID: 16010295)

  • 41. Anti-proliferative effect of curcumin on melanoma cells is mediated by PDE1A inhibition that regulates the epigenetic integrator UHRF1.
    Abusnina A; Keravis T; Yougbaré I; Bronner C; Lugnier C
    Mol Nutr Food Res; 2011 Nov; 55(11):1677-89. PubMed ID: 22045655
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Involvement of phosphodiesterase isozymes in osteoblastic differentiation.
    Wakabayashi S; Tsutsumimoto T; Kawasaki S; Kinoshita T; Horiuchi H; Takaoka K
    J Bone Miner Res; 2002 Feb; 17(2):249-56. PubMed ID: 11811555
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Changes in phosphodiesterase activity in the developing rat submandibular gland.
    Tanaka S; Shimooka S; Shimomura H
    Arch Oral Biol; 2002 Aug; 47(8):567-76. PubMed ID: 12221013
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cyclic nucleotide-mediated regulation of vascular smooth muscle cell cyclic nucleotide phosphodiesterase activity. Selective effect of cyclic AMP.
    Maurice DH
    Cell Biochem Biophys; 1998; 29(1-2):35-47. PubMed ID: 9631237
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expression and characterization of deletion recombinants of two cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE-3).
    He R; Komas N; Ekholm D; Murata T; Taira M; Hockman S; Degerman E; Manganiello VC
    Cell Biochem Biophys; 1998; 29(1-2):89-111. PubMed ID: 9631240
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Regulation of cAMP accumulation and activity by distinct phosphodiesterase subtypes in INS-1 cells and human pancreatic β-cells.
    Pratt EPS; Harvey KE; Salyer AE; Hockerman GH
    PLoS One; 2019; 14(8):e0215188. PubMed ID: 31442224
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evidence for the activity of five adenosine-3',5'-monophosphate-degrading phosphodiesterase isozymes in the adult rat neocortex.
    Sutor B; Mantell K; Bacher B
    Neurosci Lett; 1998 Aug; 252(1):57-60. PubMed ID: 9756358
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.
    Cheng J; Grande JP
    Exp Biol Med (Maywood); 2007 Jan; 232(1):38-51. PubMed ID: 17202584
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression of cAMP and cGMP-phosphodiesterase isoenzymes 3, 4, and 5 in the human clitoris: immunohistochemical and molecular biology study.
    Oelke M; Hedlund P; Albrecht K; Ellinghaus P; Stief CG; Jonas U; Andersson KE; Uckert S
    Urology; 2006 May; 67(5):1111-6. PubMed ID: 16635522
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis.
    Netherton SJ; Maurice DH
    Mol Pharmacol; 2005 Jan; 67(1):263-72. PubMed ID: 15475573
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characterization of renal ecto-phosphodiesterase.
    Jackson EK; Ren J; Zacharia LC; Mi Z
    J Pharmacol Exp Ther; 2007 May; 321(2):810-5. PubMed ID: 17308037
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of phosphodiesterase isoforms 2, 5, and 9 in the regulation of NO-dependent and NO-independent cGMP production in the rat cervical spinal cord.
    de Vente J; Markerink-van Ittersum M; Vles JS
    J Chem Neuroanat; 2006 Jun; 31(4):275-303. PubMed ID: 16621445
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthesis and evaluation of polycyclic pyrazolo[3,4-d]pyrimidines as PDE1 and PDE5 cGMP phosphodiesterase inhibitors.
    Xia Y; Chackalamannil S; Czarniecki M; Tsai H; Vaccaro H; Cleven R; Cook J; Fawzi A; Watkins R; Zhang H
    J Med Chem; 1997 Dec; 40(26):4372-7. PubMed ID: 9435906
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The calcium/calmodulin-dependent phosphodiesterase PDE1C down-regulates glucose-induced insulin secretion.
    Han P; Werber J; Surana M; Fleischer N; Michaeli T
    J Biol Chem; 1999 Aug; 274(32):22337-44. PubMed ID: 10428803
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phosphodiesterases in neurodegenerative disorders.
    Bollen E; Prickaerts J
    IUBMB Life; 2012 Dec; 64(12):965-70. PubMed ID: 23129425
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expression of cyclic nucleotide phosphodiesterase 3A in isolated rat submandibular acini.
    Shimizu K; Murata T; Hiramoto K; Sugiyama T; Nakagawa T; Manganiello VC; Tagawa T
    Arch Oral Biol; 2006 Feb; 51(2):83-8. PubMed ID: 16102722
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PDE7A is expressed in human B-lymphocytes and is up-regulated by elevation of intracellular cAMP.
    Lee R; Wolda S; Moon E; Esselstyn J; Hertel C; Lerner A
    Cell Signal; 2002 Mar; 14(3):277-84. PubMed ID: 11812656
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation.
    Gantner F; Götz C; Gekeler V; Schudt C; Wendel A; Hatzelmann A
    Br J Pharmacol; 1998 Mar; 123(6):1031-8. PubMed ID: 9559883
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prolonged beta adrenoceptor stimulation up-regulates cAMP phosphodiesterase activity in human monocytes by increasing mRNA and protein for phosphodiesterases 4A and 4B.
    Manning CD; McLaughlin MM; Livi GP; Cieslinski LB; Torphy TJ; Barnette MS
    J Pharmacol Exp Ther; 1996 Feb; 276(2):810-8. PubMed ID: 8632354
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PKA-dependent activation of PDE3A and PDE4 and inhibition of adenylyl cyclase V/VI in smooth muscle.
    Murthy KS; Zhou H; Makhlouf GM
    Am J Physiol Cell Physiol; 2002 Mar; 282(3):C508-17. PubMed ID: 11832336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.